×
About 288 results

ALLMedicine™ Stem Cell Disorders Center

Research & Reviews  97 results

Natural History and Biospecimen Acquisition for Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05350748

Jun 24th, 2022 - Background: Myelodysplastic syndromes (MDS) are heterogenous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AM...

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT04609826

Jun 21st, 2022 - This is first-in-human (FIH) Phase 1, dose escalation study of JNJ-74856665 alone or in combination with Azacitidine or Venetoclax in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Participants with Chronic Myelo...

What constitutes meaningful improvement in myelodysplastic syndromes?
https://doi.org/10.1080/10428194.2022.2084732
Leukemia & Lymphoma; Chandhok NS, Sekeres MA

Jun 15th, 2022 - Myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal stem cell disorders characterized by ineffective hematopoiesis and resulting peripheral blood cytopenias. Clinical manifestations of the disorder are varied and range from mild...

Myelodysplastic Syndrome (MDS)
https://www.merckmanuals.com/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

Jun 1st, 2022 - The myelodysplastic syndrome (MDS) is group of clonal hematopoietic stem cell disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular or hypocellular bone marrow, and a high risk of conversion to acute mye...

Myelodysplastic Syndrome (MDS)
https://www.merckmanuals.com/en-pr/professional/hematology-and-oncology/leukemias/myelodysplastic-syndrome-mds

Jun 1st, 2022 - The myelodysplastic syndrome (MDS) is group of clonal hematopoietic stem cell disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular or hypocellular bone marrow, and a high risk of conversion to acute mye...

see more →

Clinicaltrials.gov  13 results

Natural History and Biospecimen Acquisition for Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05350748

Jun 24th, 2022 - Background: Myelodysplastic syndromes (MDS) are heterogenous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AM...

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT04609826

Jun 21st, 2022 - This is first-in-human (FIH) Phase 1, dose escalation study of JNJ-74856665 alone or in combination with Azacitidine or Venetoclax in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Participants with Chronic Myelo...

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
https://clinicaltrials.gov/ct2/show/NCT01387763

Apr 27th, 2022 - Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem c...

Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
https://clinicaltrials.gov/ct2/show/NCT04177576

Mar 26th, 2021 - Myeloproliferative neoplasms (MPN) are acquired clonal hematopoietic stem cell disorders, characterized by an increase in one or more myeloid lineages. The Philadelphia chromosome negative (Ph-) MPN include polycythemia vera (PV) with an excess of...

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
https://clinicaltrials.gov/ct2/show/NCT03503409

Mar 17th, 2021 - Myelodysplastic syndrome (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenia, especially anemia, and often evolving to Acute myeloblastic Leukemia (AML). Main prognostic factors ...

see more →

News  5 results

An Introduction to Myeloproliferative Neoplasms
https://www.onclive.com/view/an-introduction-to-myeloproliferative-neoplasms

Feb 17th, 2022 - Ruben Mesa, MD:Hello and welcome to this OncLive® Peer Exchange titled Myeloproliferative Neoplasms. I’m Dr Ruben Mesa, the executive director of the Mays Cancer Center at UT Health San Antonio MD Anderson. Joining me in today’s discussions are my...

Fast Five Quiz: High-Risk Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943966

Feb 3rd, 2021 - Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. MDS may involve one, two, or three myeloid hematopoiesis cell lineages — erythrocytic, granulocytic, megak...

Carving Out New Combination Therapies in Stem Cell Disorders
https://www.onclive.com/view/carving-out-new-combination-therapies-in-stem-cell-disorders

Dec 20th, 2020 - Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement, explained William B. Donnellan, MD, director of Leukemia/Myelodysplastic Syndrome Research at Sa...

New Strategies Improve Outcomes for Lower-Risk MDS
https://www.onclive.com/view/new-strategies-improve-outcomes-for-lower-risk-mds

Dec 20th, 2020 - Myelodysplastic syndrome (MDS) is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.1,2 However, newly approved agents entering...

Topics in Pediatric Leukemia -- Myelodysplastic and Myeloproliferative Disorders of Childhood
https://www.medscape.com/viewarticle/498645

Introduction The myelodysplastic and myeloproliferative syndromes are rare in childhood, accounting for about 3% of childhood malignancies.[1] They consist of a heterogeneous group of clonal stem cell disorders characterized by ineffective hematop...

see more →